Managing Toxicities Following BCMA-Directed Immunotherapy for Myeloma

Commentary
Video

Patients treated with BCMA-directed immunotherapies for myeloma may experience susceptibility to severe infections following treatment.

BCMA, which is present in both myeloma cells and healthy cells, could suppress immune cells, making patients more susceptible to potentially fatal severe infections, according to James R. Berenson, MD.

CancerNetwork® spoke with Berenson, founder, medical and scientific director, and president and chief executive officer of the Institute for Myeloma and Bone Cancer Research, and private practitioner in West Hollywood, California, about how BCMA levels impact response to direct immune therapies and toxicities following treatment with BCMA-directed bispecific antibodies.

Berenson began by outlining a correlation between higher levels of BCMA and lower responses, emphasizing a generally more aggressive tumor state and larger tumor burden in patients with higher BCMA levels. He then expressed that treatment with BCMA-directed therapies may elicit toxicity.

The first toxicity he outlined was cytokine release syndrome (CRS), which could be fatal but typically occurs the first few days following treatment. Common symptoms include fevers and aches, among others, with severe instances mitigated with steroids. Berenson then explained that interleukin-6, an antibody target, may be a cause of CRS, and that treatment with tocilizumab (Actemra) may help to treat the toxicity.

Furthermore, Berenson explained that immune effector cell-associated neurotoxicity syndrome (ICANS) is another toxicity that may occur following treatment with BCMA-directed immune therapies. Although uncommon, Berenson explained that symptoms can occur within days and be severe, which may include seizures, Guillain-Barré syndrome, headaches, numbness, and weakness, among others.

Transcript:

in terms of patients who are getting BCMA-directed immune therapies––T cells that are called bispecific antibodies––it was thought that higher levels of BCMA may mean you are more likely to respond. It turns out, that is not the case. Consistent with all our other data, it seems that higher levels, whether it is a BCMA-directed therapy or non–BCMA-directed therapy, make it less likely you are going to respond to that treatment. That is [likely] a result of the amount of tumor that you have on board and its aggressive state, because we know that there is more of it on more aggressive myeloma. If you have worse myeloma, as well, you may have a larger tumor burden in your body than the patient who does not have that much myeloma. Therefore, you have more BCMA on the cells, and then more BCMA shed in the blood.

BCMA-directed therapies are highly effective but can be highly toxic. Early on, patients can experience an immune, overripe reaction, similar to what happens in patients, for example, who have COVID-19 infections, in which the immune system comes out unregulated. We call that cytokine release syndrome [CRS]. It can be fierce. It could be fatal. [Patients] often have fevers, do not feel well, and have aches––they can have all sorts of problems, but that usually only occurs the first few days. If it is bad, it can be mitigated with steroids.

An antibody target is one of the factors that is thought to be the culprit, and that is called interleukin-6. There is a drug called [tocilizumab; Actemra] that can help with that. It does not occur that often, but you certainly have to be aware of it. Patients are supposed to be hospitalized the first few days in case they get into trouble, [then] they can be acted upon immediately.

The other major problem they get early is called immune effector cell-associated neurotoxicity syndrome [ICANS], a neurological syndrome. [This can include] seizures, Guillain-Barré syndrome, headaches, numbness, [or] weakness. These symptoms can be severe, but again, uncommon. It usually occurs in the first few days and then goes away. There are other neurological symptoms that can occur outside of ICANS as well.

Now, as the patient traverses further, the BCMA, unfortunately, is not only present on the myeloma cells, but normal immune cells. This is a thorough take out of your immune cells, whether they are malignant or [benign] plasma cells. Thus, you are like the emperor with no clothes; you do not have an immune system. These patients get into trouble with severe infections. They can be fatal.

Recent Videos
Success with the 177Lu-PSMA-617 radioligand therapy would be transformative for the clear cell renal cell carcinoma treatment landscape.
An ongoing phase 1 trial seeks to prove XmAb819 as an effective treatment and ENPP3 as a plausible target in patients with relapsed or refractory RCC.
“The therapy is designed to prevent both CAR T-cell inactivation and to restore the anti-tumor immunity of the white blood cells that have gotten through the tumor,” said Marasco, MD, PhD.
Ongoing studies aim to combine base immunotherapy regimens with novel agents to potentially improve outcomes among patients with kidney cancer.
Investigators have found a way to reduce liver and biliary toxicity when targeting the molecule CAIX in patients with clear cell renal cell carcinoma.
Neoantigen-targeting vaccines resulted in an absence of recurrence in 9 patients with high-risk kidney cancer, according to David A. Braun, MD, PhD.
The Kidney Cancer Research Consortium may allow collaborators to form more mechanistic and scientifically driven efforts in the field.
Wayne A. Marasco, MD, PhD, stated that by targeting 2 molecules instead of 1, higher levels of tumor cell killing can be achieved in patients with clear cell renal cell carcinoma.
Leading experts in the breast cancer field highlight the use of CDK4/6 inhibitors, antibody-drug conjugates, and other treatment modalities.
Related Content
Results from the phase 3 GMMG-HD7 trial support the approval of the isatuximab-based combination in patients with newly diagnosed multiple myeloma.

Isatuximab Combo Approved in the EU for Transplant-Eligible NDMM

Roman Fabbricatore
July 25th 2025
Article

Results from the phase 3 GMMG-HD7 trial support the approval of the isatuximab-based combination in patients with newly diagnosed multiple myeloma.

Samantha Shenoy, NP, MSN, discusses how her role plays a vital part in patient care for those receiving talquetamab for multiple myeloma.

Mitigating AEs and Protecting QOL Following Talquetamab in Multiple Myeloma

Samantha Shenoy, NP, MSN
October 14th 2024
Podcast

Samantha Shenoy, NP, MSN, discusses how her role plays a vital part in patient care for those receiving talquetamab for multiple myeloma.

Subcutaneous Daratumumab Approved by EC in Smoldering Multiple Myeloma

Subcutaneous Daratumumab Approved by EC in Smoldering Multiple Myeloma

Ariana Pelosci
July 23rd 2025
Article

Results from the AQUILA trial led to the approval of subcutaneous daratumumab for patients with smoldering multiple myeloma at risk of developing the disease.

James R. Berenson, MD, describes ongoing efforts to evaluate treatment with JAK inhibitors like ruxolitinib among patients with multiple myeloma.

Exploring the Potential Role of JAK Inhibitors in Multiple Myeloma

James R. Berenson, MD, FACP
September 30th 2024
Podcast

James R. Berenson, MD, describes ongoing efforts to evaluate treatment with JAK inhibitors like ruxolitinib among patients with multiple myeloma.

A real-world analysis of teclistamab, elranatamab, and talquetamab showed comparable outcomes in relapsed or refractory multiple myeloma.

Anti-BCMA and Anti-GPRC5D BiTEs Show Similar Efficacy in Multiple Myeloma

Tim Cortese
July 13th 2025
Article

A real-world analysis of teclistamab, elranatamab, and talquetamab showed comparable outcomes in relapsed or refractory multiple myeloma.

Treatment with ISB 2001 demonstrated robust responses across difficult-to-treat multiple myeloma subgroups in the phase 1 TRIgnite-1 study.

Novel Trispecific Antibody May Offer “Renewed Hope” in R/R Multiple Myeloma

Russ Conroy
July 9th 2025
Article

Treatment with ISB 2001 demonstrated robust responses across difficult-to-treat multiple myeloma subgroups in the phase 1 TRIgnite-1 study.